MedTrace Logo

Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)

NCT00295789 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 253

Last updated 2016-09-22

No results posted yet for this study

Summary

To evaluate the clinical benefits of Paclitaxel plus Carboplatin compared with Paclitaxel plus Cisplatin in Stage IVb, Persistent, or Recurrent Cervical Cancer

Conditions

  • Uterine Cervical Neoplasms

Interventions

DRUG

chemotherapy: Paclitaxel/Cisplatin

Drug: chemotherapy: Paclitaxel/Cisplatin

DRUG

chemotherapy: Paclitaxel/Carboplatin

Drug: chemotherapy: Paclitaxel/Carboplatin

Sponsors & Collaborators

  • Ministry of Health, Labour and Welfare, Japan

    collaborator OTHER_GOV

  • Haruhiko Fukuda

    lead OTHER

Principal Investigators

  • Toshiharu Kamura, MD, PhD · Kurume University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00295789 on ClinicalTrials.gov